ELSIGHT LIMITED — Board/Management Information 2020

Jan 9, 2020

==> picture [229 x 42] intentionally omitted <==

ASX Announcement 10 January 2020

Elsight Appoints Peter Marks to Board of Directors

10 January 2020 — Elsight (ASX: “ELS”) (the “Company”) is pleased to announce the appointment of Mr Peter Ashley Marks as a Non-Executive Director of the Company effective immediately.

Peter brings over 30 years’ experience in corporate advisory and investment banking to the Board. Over the course of his esteemed career, he has specialised in capital raising IPOs, cross border M&A transactions, corporate underwriting, and venture capital transactions for companies in Australia, the U.S., and Israel. He has been involved in a very broad range of transactions, with a special focus in the life sciences, biotechnology, medical technology and the high tech segments.

Peter has served as both an Executive and Non-Executive Director of a number of different entities which have been listed on the ASX, NASDAQ, and AIM markets. Currently, he is a Director of Alterity Therapeutics Limited (ASX:ATH and NASDAQ:ATHE), Non-Executive Director of Noxopharm Limited (ASX: NOX), Nyrada Inc, and Non-Executive Director of Fluence Corporation Ltd (ASX: FLC). He holds an MBA from the University of Edinburgh, Scotland, and a Bachelor of Economics, Bachelor of Laws and a Graduate Diploma in Commercial Law from Monash University, Australia.

Peter brings invaluable experience to the Board of Directors, and his corporate expertise accrued over his long career will be an important asset to the Company.

Commenting on his appointment, Peter said, “I am pleased to be joining Elsight as a Non-Executive Director at this time, and am excited to be working with the Company and its Directors as the commercialisation of Halo accelerates. I look forward to contributing to this effort and bringing my connections and corporate experience to the Board.”

“We are extremely pleased that Peter has joined the Board of Elsight,” said Nir Gabay, Elsight’s CEO. “His vast and diverse experience across a broad range of sectors and his exceptional business and legal acumen will be of enormous value to the Company in 2020 and beyond.”

Authorised for release by the Board of Directors of Elsight Limited.

• ENDS -

For more information, please contact:

Corporate Enquiries

Justin Rosenberg Gleneagle Securities T: +61 2 8277 6683 E: justin.rosenberg@gleneagle.com.au

Australian Business & Media Enquiries

Howard Digby Elsight Limited T: +61 434 987 750

E: howarddigby@gmail.com

About Elsight

Elsight (www.elsight.com), is a solution provider of ground-breaking hybrid video and data transport services (on-the-move or fixed) for large Safe-City projects, sensitive facilities management, and surveillance and protective activities. The platform supports video capturing, recording, and highly secured transmission against video interception and hacking. Elsight ’s platform was designed to address the most demanding requirements of Special Forces across enemy lines and sophisticated intelligence organizations. These systems underwent the most rigorous testing in combat situations as well as extensive testing by the most demanding laboratories. As a result, they present an unmatched level of reliability, lowest latency, and highest adaptive bandwidth over cellular networks that enables HD and 4K tv transmission quality, with “never-fail” redundancy and much more. For the first time they offer strict military requirements for civil usage. Elsight ’s customers range from defence and homeland security, industrial security, broadcasting, first responders and healthcare.